Literature DB >> 25349628

Intragenic duplication of EHMT1 gene results in Kleefstra syndrome.

Eva Maria Christina Schwaibold1, Mateja Smogavec1, Elke Hobbiebrunken2, Lorenz Winter1, Barbara Zoll1, Peter Burfeind1, Knut Brockmann2, Silke Pauli1.   

Abstract

BACKGROUND: Kleefstra syndrome is characterized by intellectual disability, muscular hypotonia in childhood and typical facial features. It results from either a microdeletion of or a deleterious sequence variant in the gene euchromatic histone-lysine N-methyltransferase 1 (EHMT1) on chromosome 9q34.
RESULTS: We report on a 3-year-old girl with characteristic symptoms of Kleefstra syndrome. Array comparative genomic hybridization analysis revealed a 145 kilobases duplication spanning exons 2 to 10 of EHMT1. Sequence analysis characterized it as an intragenic tandem duplication leading to a frame shift with a premature stop codon in EHMT1.
CONCLUSIONS: This is the first description of an intragenic duplication of EHMT1 resulting in Kleefstra syndrome.

Entities:  

Keywords:  Array CGH; EHMT1; Haploinsufficiency; Intragenic duplication; KS; Kleefstra syndrome

Year:  2014        PMID: 25349628      PMCID: PMC4209064          DOI: 10.1186/s13039-014-0074-7

Source DB:  PubMed          Journal:  Mol Cytogenet        ISSN: 1755-8166            Impact factor:   2.009


Background

Kleefstra syndrome (KS; OMIM #610253) is a clinically well described genetic disorder characterized by the phenotypical core features of psychomotoric retardation/intellectual disability (ID), muscular hypotonia and characteristic facial dysmorphisms. The underlying cause of KS is - in approximately 75% - a microdeletion in the chromosomal region 9q34 leading to either a partial or an entire EHMT1 loss [1-4]. The other causes of KS are heterozygous intragenic loss-of-function mutations in the EHMT1 gene (~25%; OMIM *607001) [1-4]. There seems to be no clear genotype-phenotype correlation regarding patients with microdeletions in 9q34 and intragenic mutations in EHMT1 [3,4]. Duplications of the entire or partial EHMT1 gene have been reported [5,6] but none of these duplications was strictly intragenic and none of them led to a KS phenotype. EHMT1 encodes for a methyltransferase specific for lysine-9 of histone H3 and is a component of the transcription factor E2F6, which can repress gene transcription [7]. E2F6-methylation by EHMT1 is probably important for transcriptional inactivation via chromatin remodeling [7]. Here, we describe for the first time a patient with the typical symptoms of KS carrying a 145 kilobases (kb) intragenic duplication in the EHMT1 gene. The submicroscopic duplication in EHMT1 was detected by array comparative genomic hybridization (aCGH). Transcript analysis revealed a tandem duplication leading to a frame shift and a premature stop codon, suggesting haploinsufficiency as the underlying cause of KS [1,3,8].

Case presentation

Case report

The patient is the third child of healthy non-consanguinous parents. She has two healthy older brothers. Her mother had an intellectually disabled half-brother. Her father’s paternal uncle died directly after birth for unknown reasons. Prenatal ultrasound demonstrated a fetal constitutional growth delay, a polyhydramnion and a single umbilical artery. The girl was born spontaneously at 39 weeks gestation. Her birth length, her birth weight and her head circumference were between the 3rd and the 10th centile. Apgar scores were 9/9/9. Developmental delay was first noted at 3 months of age. The girl showed marked muscular hypotonia. At 2 years of age she could sit without support but was still not able to crawl or walk at the age of 3 years. She tended to be very quiet and did not react to sounds. A hearing test was anamnestically normal. The girl began to vocalize and starts teeth grinding when she was one year old but she could not speak at the age of 3 years. She displayed autistic features with stereotypic movements and the vocalization of clicking voices with her tongue. At 3 years of age she attended a special nursery. Cranial MRIs at the age of 2 and 3 years, respectively, revealed unspecific bilateral T2-hyperintense white matter changes in the occipital region. An electroencephalogram at the age of 3 years was normal. Echocardiography demonstrated a haemodynamically irrelevant patent foramen ovale and a mild peripheral pulmonary stenosis. Myocardial function was normal. At 2 11/12 years of age the patient displayed the following facial features (Figure 1a-b): square, brachycephalic face with a prominent forehead and frontal bossing, slight midface hypoplasia, hypertelorism with mildly downslanting palpebral fissures, synophris, small nose with anteverted nostrils and deep-set nasal root, mild prognathism, deep-set posterior rotated ears, full cheeks and prominent philtrum. The girl held her mouth mostly opened with a cupid bowed upper lip, full lower lip and a slightly protruding tongue. An ophthalmologic examination confirmed an intermittent exotrophy. The patient’s soles of the feet were deeply creased in their frontal part (Figure 1c). Her back was hairy (Figure 1d).
Figure 1

Representative photographs of the patient at 2 11/12 years of age. (a-b) The main facial features of the girl were: brachycephaly, prominent forehead, hypertelorism with mildly downslanting palpebral fissures, intermittent exotrophy, synophris, small nose with anteverted nostrils and deep-set nasal root, mild prognathism, deep-set posterior rotated ears, full cheeks and prominent philtrum. Note the mostly opened mouth with cupid bowed upper lip and full lower lip. (c) The frontal part of her plantar feet was deeply creased. (d) Her back was hairy.

Representative photographs of the patient at 2 11/12 years of age. (a-b) The main facial features of the girl were: brachycephaly, prominent forehead, hypertelorism with mildly downslanting palpebral fissures, intermittent exotrophy, synophris, small nose with anteverted nostrils and deep-set nasal root, mild prognathism, deep-set posterior rotated ears, full cheeks and prominent philtrum. Note the mostly opened mouth with cupid bowed upper lip and full lower lip. (c) The frontal part of her plantar feet was deeply creased. (d) Her back was hairy.

Results

Array CGH analysis in our patient revealed a subterminal duplication on chromosome 9q34.4. The size was approximately 145 kb, spanning positions 140.535.164 to 140.657.526 (arr 9q34.3(140,527,261x2,140,535,164-140,657,526x3,140,672,499x2); GRCh37/hg19; ISCN 2013; Figure 2a). The duplication was verified by qPCR (data not shown). The parents’ array CGH analyses as well as standard karyotyping were normal (data not shown) confirming the de novo origin of the duplication.
Figure 2

Microduplication within gene results in KS. (a) aCGH identified a 145 kb duplication (greenish shaded; enlarged on the right side of Figure 2a) within the EHMT1 gene (arrow) on chromosome 9q34.4. Log 2 ratio data for two dye-swap plots (patient/control) are presented according to their positions in the human genome. The light blue shaded region with blue and red dots indicates the moving average. Chr.9: chromosome 9. (b) Schematic overview of the two possible cDNA transcripts of EHMT1 gene in our patient that seemed most likely. Black: normal EHMT1 gene transcript. Red: duplicated region of EHMT1 in our patient. ex: exon. A: indicates a possible PCR product (exon 10 of the duplicated region adjacent to exon 2 of the normal EHMT1 transcript). B: indicates a possible PCR product (exon 2 of the duplicated region adjacent to exon 11 of normal coding EHTM1 transcript). (c) Agarose gel electrophoresis of possible PCR products A and B (see Figure 2b) in our patient (first and second lane) and a control person (third and forth lane). A PCR product was only seen for A in our patient. It showed the expected size of ~190 bp of PCR product A according to the 1 kb Plus DNA Ladder (Invitrogen, Carlsbad, CA). (d) Sequence analysis of PCR product A (Figure 2c) and comparison with the normal coding transcript of EHTM1 gene revealed a frameshift in the coding sequence leading to a premature stop codon (green box) in EHMT1 in our patient. Exon 10 adjacent to exon 2 of the forward strand of EHMT1 coding sequence in our patient is shown. Grey shaded boxes: localization of the constructed forward (fw) and reverse (rv) primers, respectively. Black: coding sequence of exon 10 of EHMT1. Red: coding sequence of exon 2 of EHMT1.

Microduplication within gene results in KS. (a) aCGH identified a 145 kb duplication (greenish shaded; enlarged on the right side of Figure 2a) within the EHMT1 gene (arrow) on chromosome 9q34.4. Log 2 ratio data for two dye-swap plots (patient/control) are presented according to their positions in the human genome. The light blue shaded region with blue and red dots indicates the moving average. Chr.9: chromosome 9. (b) Schematic overview of the two possible cDNA transcripts of EHMT1 gene in our patient that seemed most likely. Black: normal EHMT1 gene transcript. Red: duplicated region of EHMT1 in our patient. ex: exon. A: indicates a possible PCR product (exon 10 of the duplicated region adjacent to exon 2 of the normal EHMT1 transcript). B: indicates a possible PCR product (exon 2 of the duplicated region adjacent to exon 11 of normal coding EHTM1 transcript). (c) Agarose gel electrophoresis of possible PCR products A and B (see Figure 2b) in our patient (first and second lane) and a control person (third and forth lane). A PCR product was only seen for A in our patient. It showed the expected size of ~190 bp of PCR product A according to the 1 kb Plus DNA Ladder (Invitrogen, Carlsbad, CA). (d) Sequence analysis of PCR product A (Figure 2c) and comparison with the normal coding transcript of EHTM1 gene revealed a frameshift in the coding sequence leading to a premature stop codon (green box) in EHMT1 in our patient. Exon 10 adjacent to exon 2 of the forward strand of EHMT1 coding sequence in our patient is shown. Grey shaded boxes: localization of the constructed forward (fw) and reverse (rv) primers, respectively. Black: coding sequence of exon 10 of EHMT1. Red: coding sequence of exon 2 of EHMT1. The only gene in the duplicated region was EHMT1 (Figure 2a). According to the array CGH results the centromerically located breakpoint of the duplication was within intron 1 of EHMT1, the terminally located breakpoint was between intron 10 and exon 13 of EHMT1. As microdeletions as well as sequence variants but not microduplications of or within EHMT1 are known to cause KS and our patient’s symptoms were typical for KS the possible pathogenic background was examined. First, the terminal breakpoint of the duplication was narrowed down to intron 10 of EHMT1 by qPCR using exon-specific primers for the chromosomal region between positions 140.535.164 to 140.657.526. It was demonstrated that the duplication spanned exon 2 to exon 10 of EHTM1 (data not shown). There were several possibilities regarding the localization and the orientation of the duplication but one of the two RNA transcripts shown in Figure 2b seemed most likely. Therefore, PCRs with the patient’s cDNA and primer sequences specific for the possible PCR products A (exon 10 adjacent to exon 2 of the coding EHTM1 gene) and B (exon 2 adjacent to exon 11 of the coding EHTM1 gene), respectively, were performed. Primers for the PCR product of exon 10 adjacent to exon 11 and the PCR product spanning exons 2 to 10, respectively, were used as positive controls for the primer function (data not shown). A PCR product was only obtained for A (Figure 2c, first lane) and for the positive controls (data not shown), not for B (Figure 2c, second lane) and not with the DNA sample of a control person (Figure 2c, third and fourth lane). By obtaining this PCR product transcript degradation that would be suggestive for nonsense mediated mRNA decay seemed to be rather unlikely. PCR product A was directly sequenced and compared with the sequences of both, exon 2 and exon 10, in wildtype EHMT1 (ENST00000460843). The duplication within EHMT1 resulted in a frameshift and a premature stop codon in the additionally inserted exon 2 of the EHMT1 transcript in our patient (Figure 2d).

Discussion

Array CGH revealed a 145 kb duplication within the EHMT1 gene in our patient (Figure 2a). A detailed analysis of the duplicated region within EHMT1 in our patient by qPCR and cDNA analysis revealed a direct tandem duplication of exons 2 to 10 of the EHMT1 gene (Figure 2c). Patients with duplications in the region of EHMT1 have been reported [5,6] but the duplications included either the whole EHMT1 gene, additionally the adjacent chromosomal region or one or multiple adjacent genes. Only one patient with a EHMT1 duplication spanning exons 1 to 16 is described in the literature [5]. This patient does not display a KS phenotype but autistic features and behavioral problems [5]. The patient had a tandem duplication with both copies of EHMT1 being probably functional. Due to the duplication in our patient a premature stop codon in the additionally inserted exon 2 is generated (Figure 2d). It is very likely that the premature termination of the protein EHMT1 will impair or reduce its function although we could not directly prove haploinsufficiency of EHMT1. In contrast, increased dosage of EHMT1 - as in the other patient - might lead to neurodevelopmental impairment [5]. A possible explanation for the location of the duplication in our patient could be the existence of repetitive DNA elements in EHMT1 in the breakpoint region of the duplication. Repetitive DNA elements in general - and Alu elements in particular - are prone for non-allelic homologues recombinations that can lead to disease causing chromosomal aberrations [9]. According to the RepeatMasker Web Server [10] both, intron 1 and intron 10 of EHMT1 gene, contain high amounts of repetitive DNA elements (intron 1: 58,13% total interspersed repeats (TIRs); intron 10: 49,07% TIRs). The adjacent introns 2, 9 and 11, respectively, have lower amounts of repetitive elements. In intron 1 especially the amount of Alu elements that belong to the short interspersed elements was higher than in intron 2 (31,53% vs. 19.30%). The high rate of repetitive elements - especially Alu elements - in the breakpoint regions of the duplication in our patient provides a plausible explanation for the localization of the duplication. Likely, there will be further KS patients with deletions or duplications leading to haploinsufficiency of EHMT1 with chromosomal breakpoints in one or both of the affected introns reported here. Our patient displayed the typical phenotype of KS [1-4,11]; (Table 1). Only minor phenotypical differences were observed, e.g. our patient had a very hairy back and was almost underweight, both features not typically seen in KS.
Table 1

Clinical findings of our patient compared with previously reported KS patients and defects in

Overlapping features Our patient Previously reported patients with KS and EHMT1 defect (%)
Psychomotoric retardation/ ID+100%
Childhood hypotonia+100%
Behavioural problems+ (autistic features)75%
Facial dysmorphisms:
  Midface hypoplasia+80%
  Synophris+60%
  Dysplastic/posterior rotated ears+50%
  Short/small nose+45%
  Brachycephaly+40%
  Protruding tongue/macroglossia+40%
  Hypertelorism+30%
  Anteverted nostrils+25%
  Tented/cupid-bowed upper lip+25%
  Thick/everted lower lip+25%
  Pointed chin+25%
Different features
Overweight-45%
Facial dysmorphisms:
  Arched eyebrows-30%
  Pointed chin-25%
  Prominent forehead+n. r.
Neurologic defects:
  Structural CNS anomalies-n. r.
  Seizures-25%
Renal anomalies-15%
Sensorineural hearing loss-15%
Deeply creased soles of the feet+n. r.
Hairy back+n. r.

+ denotes present, − denotes absent; n. r. = not reported; KS = Kleefstra syndrome; ID = intellectual disability; Table modified from [11].

Clinical findings of our patient compared with previously reported KS patients and defects in + denotes present, − denotes absent; n. r. = not reported; KS = Kleefstra syndrome; ID = intellectual disability; Table modified from [11].

Conclusions

For the first time we could show that a duplication within the EHMT1 gene leads to KS in a patient due to the creation of a premature stop codon in EHMT1 that will probably impair/reduce the protein function. The gene EHMT1 seems to be dosage sensitive with a decrease of gene expression resulting in KS and an increase of gene expression leading to a milder phenotype with an impaired neurodevelopment. The phenotype displayed by our patient is very similar compared with the previously reported KS patients and confirms the notion that there is no strong genotype-phenotype correlation in KS.

Methods

DNA and RNA preparation

Blood samples were collected from the patient and her parents after obtaining the parents’ signed informed consent. Total genomic DNA was prepared using standard techniques. RNA isolation was performed from a blood sample of our patient using the PAXgene™ Blood RNA kit 50v2 (PreAnalytix, Qiagen, Venlo, The Netherlands) according to the manufacturer’s instructions. cDNA was obtained using the Superscript II Kit (Invitrogen, Carlsbad, CA).

aCGH

Genome-wide copy number scans were performed with the patient’s and her parents’ lymphocyte DNA using an Agilent SurePrint G3 Human CGH Microarray Kit 4 × 180 K and was read using an Agilent Microarray Scanner G256BA and G5761A, respectively, along with Agilent Feature Extraction Software V9.1 (Agilent Technologies, Inc., Santa Clara, CA) according to the manufacturer’s instructions. The results were analyzed using Agilent Cytogenomics 2.0 and 2.5 software, respectively. Array CGH data was confirmed by quantitative real time PCR (qPCR).

EHMT1 gene analysis

qPCR was used to narrow down the C-terminal breakpoint in the EHMT1 gene by designing specific primers for exon 6 to 17 of the EHMT1 gene (ENST00000460843). PCRs were performed to amplify the possible transcripts of the EHMT1 gene in our patient. The obtained PCR products were directly sequenced on the ABI 3500xL Genetic Analyzer (Applied Biosystems, Foster City, CA). Their sequence was compared with the sequence of normal EHMT1 coding transcript (ENST00000460843). All primer sequences and PCR conditions are available on request.

Cytogenetic analysis

Metaphase chromosome spreads of blood samples of the patient’s parents were prepared from phytohemagglutinin (PHA)-stimulated peripheral blood cultures using standard protocols. 10 and 11, respectively, GTG-banded metaphases were analyzed.

Consent

Written informed consent was obtained from the parents of the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
  10 in total

1.  A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells.

Authors:  Hidesato Ogawa; Kei-Ichiro Ishiguro; Stefan Gaubatz; David M Livingston; Yoshihiro Nakatani
Journal:  Science       Date:  2002-05-10       Impact factor: 47.728

2.  Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability.

Authors:  Tjitske Kleefstra; Jamie M Kramer; Kornelia Neveling; Marjolein H Willemsen; Tom S Koemans; Lisenka E L M Vissers; Willemijn Wissink-Lindhout; Michaela Fenckova; Willem M R van den Akker; Nael Nadif Kasri; Willy M Nillesen; Trine Prescott; Robin D Clark; Koenraad Devriendt; Jeroen van Reeuwijk; Arjan P M de Brouwer; Christian Gilissen; Huiqing Zhou; Han G Brunner; Joris A Veltman; Annette Schenck; Hans van Bokhoven
Journal:  Am J Hum Genet       Date:  2012-06-21       Impact factor: 11.025

3.  Human gene copy number spectra analysis in congenital heart malformations.

Authors:  Aoy Tomita-Mitchell; Donna K Mahnke; Craig A Struble; Maureen E Tuffnell; Karl D Stamm; Mats Hidestrand; Susan E Harris; Mary A Goetsch; Pippa M Simpson; David P Bick; Ulrich Broeckel; Andrew N Pelech; James S Tweddell; Michael E Mitchell
Journal:  Physiol Genomics       Date:  2012-02-07       Impact factor: 3.107

4.  Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome.

Authors:  Tjitske Kleefstra; Han G Brunner; Jeanne Amiel; Astrid R Oudakker; Willy M Nillesen; Alex Magee; David Geneviève; Valérie Cormier-Daire; Hilde van Esch; Jean-Pierre Fryns; Ben C J Hamel; Erik A Sistermans; Bert B A de Vries; Hans van Bokhoven
Journal:  Am J Hum Genet       Date:  2006-06-13       Impact factor: 11.025

Review 5.  Alu repeats and human disease.

Authors:  P L Deininger; M A Batzer
Journal:  Mol Genet Metab       Date:  1999-07       Impact factor: 4.797

6.  Disruption of the gene Euchromatin Histone Methyl Transferase1 (Eu-HMTase1) is associated with the 9q34 subtelomeric deletion syndrome.

Authors:  T Kleefstra; M Smidt; M J G Banning; A R Oudakker; H Van Esch; A P M de Brouwer; W Nillesen; E A Sistermans; B C J Hamel; D de Bruijn; J-P Fryns; H G Yntema; H G Brunner; B B A de Vries; H van Bokhoven
Journal:  J Med Genet       Date:  2005-04       Impact factor: 6.318

7.  Human subtelomeric copy number gains suggest a DNA replication mechanism for formation: beyond breakage-fusion-bridge for telomere stabilization.

Authors:  Svetlana A Yatsenko; Patricia Hixson; Erin K Roney; Daryl A Scott; Christian P Schaaf; Yu-tze Ng; Robbin Palmer; Richard B Fisher; Ankita Patel; Sau Wai Cheung; James R Lupski
Journal:  Hum Genet       Date:  2012-08-14       Impact factor: 4.132

8.  Update on Kleefstra Syndrome.

Authors:  M H Willemsen; A T Vulto-van Silfhout; W M Nillesen; W M Wissink-Lindhout; H van Bokhoven; N Philip; E M Berry-Kravis; U Kini; C M A van Ravenswaaij-Arts; B Delle Chiaie; A M M Innes; G Houge; T Kosonen; K Cremer; M Fannemel; A Stray-Pedersen; W Reardon; J Ignatius; K Lachlan; C Mircher; P T J M Helderman van den Enden; M Mastebroek; P E Cohn-Hokke; H G Yntema; S Drunat; T Kleefstra
Journal:  Mol Syndromol       Date:  2012-01-24

9.  Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype.

Authors:  T Kleefstra; W A van Zelst-Stams; W M Nillesen; V Cormier-Daire; G Houge; N Foulds; M van Dooren; M H Willemsen; R Pfundt; A Turner; M Wilson; J McGaughran; A Rauch; M Zenker; M P Adam; M Innes; C Davies; A González-Meneses López; R Casalone; A Weber; L A Brueton; A Delicado Navarro; M Palomares Bralo; H Venselaar; S P A Stegmann; H G Yntema; H van Bokhoven; H G Brunner
Journal:  J Med Genet       Date:  2009-03-04       Impact factor: 6.318

Review 10.  The chromosome 9q subtelomere deletion syndrome.

Authors:  Douglas R Stewart; Tjitske Kleefstra
Journal:  Am J Med Genet C Semin Med Genet       Date:  2007-11-15       Impact factor: 3.908

  10 in total
  5 in total

1.  Kleefstra-variant syndrome with heterozygous mutations in EHMT1 and KCNQ2 genes: a case report.

Authors:  Giovanna Marchese; Francesca Rizzo; Anna Guacci; Alessandro Weisz; Giangennaro Coppola
Journal:  Neurol Sci       Date:  2016-01-20       Impact factor: 3.307

2.  A Novel Partial Duplication of ZEB2 and Review of ZEB2 Involvement in Mowat-Wilson Syndrome.

Authors:  Adrianne L Baxter; Jay L Vivian; R Tanner Hagelstrom; Waheeda Hossain; Wendy L Golden; E Robert Wassman; Rena J Vanzo; Merlin G Butler
Journal:  Mol Syndromol       Date:  2017-05-03

3.  Genetic Counselling Pitfall: Co-Occurrence of an 11.8-Mb Xp22 Duplication and an Xp21.2 Duplication Disrupting IL1RAPL1.

Authors:  Nicolas Chatron; Lucie Thibault; James Lespinasse; Audrey Labalme; Caroline Schluth-Bolard; Marianne Till; Patrick Edery; Renaud Touraine; Vincent des Portes; Gaetan Lesca; Damien Sanlaville
Journal:  Mol Syndromol       Date:  2017-09-07

4.  Case Report: Long-Term Treatment and Follow-Up of Kleefstra Syndrome-2.

Authors:  Dandan Wu; Rong Li
Journal:  Front Pediatr       Date:  2022-05-24       Impact factor: 3.569

5.  New insights into genetic variant spectrum and genotype-phenotype correlations of Rubinstein-Taybi syndrome in 39 CREBBP-positive patients.

Authors:  Virginia Pérez-Grijalba; Alberto García-Oguiza; María López; Judith Armstrong; Sixto García-Miñaur; Jose María Mesa-Latorre; Mar O'Callaghan; Mercé Pineda Marfa; Maria Antonia Ramos-Arroyo; Fernando Santos-Simarro; Verónica Seidel; Elena Domínguez-Garrido
Journal:  Mol Genet Genomic Med       Date:  2019-09-30       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.